BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

講師

國鼎生物科技股份有限公司

 

Company Info

Name /Golden Biotechnology Corp

Address /15F, No. 27- 6, Sec.2, Zhongzheng E. Rd., Tamsui Dist., New Taipei City 251, Taiwan .

Website /www.goldenbiotech.com

Presenter

Name /Boon-Kean Choy

Title /General Manager

Email /bkchoy@goldenbiotech.com

Telephone /+886-2-2808-6006

Fax /+886-2-2808-6005

Mobile /

Company Type

Pharmaceutical

About the Company

Golden Biotechnology Corporation, founded in 2002, is a Taiwanese based leading bio-pharmaceutical company which dedicates to discovering novel compounds (NCE) and developing cutting-edge innovative therapeutics with breakthrough advantage against serious and rare diseases in hopes to improve and promote a lasting quality of life, health and longevity.

Brief Description of main products or services

Antroquinonol®, a novel small molecule that was discovered in 2006 by Golden Biotechnology Corp. (GBC,GoldenBiotech). GoldenBiotech announces topline results in Jan. 2022 from the unblinded COVID-19 trial for oral new drug Antroquinonol in hospitalized mild, moderate and severe patients. The clinical trial data revealed for Primary Outcome Measure: recover ratio for the proportion of patients who are alive and free of respiratory failure (e.g., no need for invasive mechanical ventilation, non-invasive ventilation, high flow oxygen, or ECMO) on Day 14.

Result: In the Antroquinonol group, the recovery ratio was 97.9% at the day 14 visit. Furthermore, no death or respiratory failure was found in the Antroquinonol group at the day 28 visit with recovery ratio of 100%.

Antroquinonol is a new small molecule drug (NCE) with convenient oral administration design and distinguished from other emerging oral treatment drugs for COVID-19 by its multi-functional effects on anti-viral, anti-inflammation and anti-fibrosis characteristics revealed by studies.

GoldenBiotech discovered from its own screening platforms Antroquinonol® (trade name HOCENA® ), which has been granted more than 150 patents worldwide for its structure, preparation and applications in oncology, cardio-metabolic syndromes, autoimmune diseases, neurodegenerative diseases and infectious diseases. Since 2013, Antroquinonol® was authorized Phase II clinical trial on NSCLC by US FDA and Taiwan FDA and trial completed in 2019. The clinical trials on acute myeloid leukemia (AML) has also completed in 2020, and the multi-national trials on pancreatic cancer and COVID-19 expected to accomplish in 2022. Orphan Drug Designations (ODD) were obtained in treatment of pancreatic cancer (US #14-4608 & EU), AML (US#15-4763) and hepatocellular carcinoma (US#15-4881).

Antroquinonol® exhibits a broad spectrum of activities against malignancies in-vivo and in-vitro, and offers a better solution than the single-action compounds the industry developed so far. Antroquinonol’s multiple, simultaneous, and synergistic actions enable positive outcomes. Antroquinonol® can be used as a monotherapy, combination- or adjuvant-therapy to complement other drugs, or as a best supportive care. Demonstrated safety profile and efficacy make Antroquinonol® an ideal asset in treating diseases and improving overall quality of life of patients.

GoldenBiotech is seeking for out-licensing and/or co-development opportunities to further clinical ,development and commercialization.

Contact Person

Name /Charles Yeh / Associate Vice President

Email /charlesyeh@goldenbiotech.com

Phone /0972626016